Your session is about to expire
Metaglip vs Metformin
Introduction
For patients diagnosed with type 2 diabetes, certain medications that regulate the levels of glucose in the blood can help manage symptoms and prevent complications. Metaglip and Metformin are two such drugs commonly prescribed for this condition. They each work differently to control blood sugar levels but both have been effective in managing type 2 diabetes.
Metaglip is a combination medication containing glipizide, which stimulates the pancreas to release more insulin, and metformin, which decreases glucose production by the liver while also increasing sensitivity to insulin in muscle and fat cells.
On the other hand, Metformin alone works primarily by reducing glucose production in the liver and improving your body's sensitivity to insulin so that your body uses it more effectively. While they both aim at controlling high blood sugar levels, their mechanisms differ slightly due to how they interact with different organs within your body.
Metaglip vs Metformin Side By Side
| Attribute | Metaglip | Metformin |
|---|---|---|
| Brand Name | Metaglip | Metformin |
| Contraindications | Should not be taken if you are taking or have recently taken medications for heart disease (particularly those containing iodine), diuretics, steroids, blood pressure medication, or other diabetes medicines without consulting with your physician. | Should not be taken if you have severe kidney disease, metabolic acidosis, or if you are in a state of diabetic ketoacidosis. |
| Cost | For brand name, around $450 for 60 tablets (2.5/500 mg). For generic (Glipizide-Metformin), costs vary but typically range between $0.20 to over a dollar per day depending on dosage and quantity. | For brand name (Glucophage), about $390 for 60 tablets (500 mg). Generic versions can cost as low as $0.01 to around $0.50 per day depending on dosage and quantity. |
| Generic Name | Glipizide-Metformin | Metformin |
| Most Serious Side Effect | Hypoglycemia, Lactic Acidosis | Lactic Acidosis |
| Severe Drug Interactions | Medications for heart disease, diuretics (water pills), steroids, blood pressure medication, other diabetes medicines. | Iodinated contrast agents, alcohol, cimetidine, diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. |
| Typical Dose | One tablet (containing metformin hydrochloride 500mg and glipizide 2.5mg) twice daily with meals; adjusted based on response. | 500 mg taken twice daily or 850 mg once daily, increased gradually up to a maximum of 2000-2550 mg per day divided into two or three doses. |
What is Metaglip?
Metaglip is a combination drug that contains two active ingredients, glipizide and metformin. Glipizide belongs to the class of drugs known as sulfonylureas and works by stimulating the pancreas to produce more insulin. Metformin is a biguanide which reduces glucose production in the liver, enhances insulin sensitivity, and improves glucose utilization by muscles. The combined effect of these two medications helps control blood sugar levels in patients with type 2 diabetes.
On the other hand, Metformin alone was approved by FDA back in 1994 for treating type 2 diabetes mellitus. It primarily decreases hepatic glucose production while increasing insulin sensitivity in peripheral tissues. Unlike Metaglip, it does not stimulate pancreatic beta cells to increase insulin secretion; hence there's no risk of hypoglycemia when used as monotherapy.
Both drugs are effective at controlling high blood sugar but they operate differently within your body system. As such, side effects may vary between them with Metaglip potentially causing hypoglycaemic episodes due to its sulfonylurea component.
What conditions is Metaglip approved to treat?
Metaglip is approved for the treatment of various conditions, primarily:
- Type 2 diabetes mellitus in adults who do not achieve adequate glycemic control on metformin or glipizide alone
- Combination therapy in type 2 diabetes mellitus when diet and exercise plus dual therapy with any two of the following are inadequate: metformin, sulfonylurea, or glipizide.
How does Metaglip help with these illnesses?
Metaglip assists in the management of type 2 diabetes by combining the actions of two drugs, metformin and glipizide. Metformin works primarily by reducing glucose production in the liver and improving your body's sensitivity to insulin so that your body can use insulin more effectively. On the other hand, glipizide stimulates the pancreas to produce more insulin.
Insulin is a hormone that controls how sugar moves from blood into cells where it's used for energy. In individuals with type 2 diabetes, their bodies either don't produce enough insulin or they resist its effects leading to elevated levels of blood sugar. By enhancing your body’s response to its own insulin and decreasing glucose production in the liver through metformin along with augmenting pancreatic insulin secretion via glipizide, Metaglip can reduce overall blood sugar levels helping patients better manage their condition.
What is Metformin?
Metformin, often sold under the brand name Glucophage among others, is a first-line treatment for type 2 diabetes. This medication works by reducing glucose production in the liver and improving your body's sensitivity to insulin so that your body uses insulin more effectively. Metformin was first approved by the FDA in 1994. Unlike Metaglip, which combines two oral antihyperglycemic agents (glipizide and metformin), metformin alone does not increase insulin levels in the bloodstream and therefore does not cause hypoglycemia when used alone. Its lack of action on insulin levels means its side-effect profile is also different from those medications combining multiple antihyperglycemic agents like Metaglip; particularly it does not cause weight gain or significant hypoglycemia (common side effects of drugs such as Metaglip). The effects of increasing insulin sensitivity can be beneficial for managing blood sugar levels, especially in patients who do not respond well to "typical" dual therapy drugs such as Metaglip.
What conditions is Metformin approved to treat?
Metformin is a first-line medication approved for the management of:
- Type 2 diabetes mellitus in adults
- Polycystic ovary syndrome (PCOS) It's often prescribed as part of an overall treatment plan that includes diet and exercise to control high blood sugar and prevent associated health complications.
How does Metformin help with these illnesses?
Metformin is a first-line medication for the treatment of type 2 diabetes, particularly in overweight patients. It works by decreasing glucose production by the liver and increasing insulin sensitivity, thus enhancing glucose uptake and utilization throughout your body. This helps to lower blood sugar levels in individuals with diabetes, reducing their risk of complications such as heart disease or kidney damage. Metformin's action on these metabolic processes makes it an effective choice for managing this chronic condition. On the other hand, Metaglip is a combination medication that includes both metformin and another drug called glipizide which stimulates pancreatic cells to produce more insulin. While offering dual-action control over diabetes symptoms, it may not be suitable for all patients due to potential side effects related to glipizide component unlike metformin alone.
How effective are both Metaglip and Metformin?
Both Metaglip, a combination product containing glipizide and metformin, and metformin alone have been widely used in managing type 2 diabetes. They were approved by the FDA several years apart with metformin being introduced first. Since they act on different aspects of insulin regulation, their usage might differ based on patient needs. A direct comparison of Metaglip to metformin monotherapy was conducted in a double-blind clinical trial; both treatment modalities demonstrated similar efficacy in lowering HbA1c levels (a key marker for long-term blood glucose control) but Metaglip showed superior ability to reduce fasting plasma glucose levels.
In a 2006 meta-analysis review focused on biguanides like metformin, it was found that they are effective at improving glycemic control from the onset of therapy. Its side effect profile is generally favorable when compared to other anti-diabetic medications as it does not induce weight gain or hypoglycemia when used alone. The same study reports that due to its safety profile and effectiveness at reducing cardiovascular events, it has become one of the most commonly prescribed antidiabetic drugs globally.
Metaglip's unique pharmacological properties make it an interesting choice for patients who do not respond well solely to initial treatment with metformin or those who require additional glycemic control without resorting to injectable therapies such as insulin. However, data confirming its efficacy as a stand-alone treatment is less robust than that for standalone use of either component drug: glipizide or metformin. Nonetheless, because this medication combines two distinct mechanisms of action – increasing insulin production (glipizide) and decreasing hepatic gluconeogenesis while increasing peripheral sensitivity to insulin (metformin), there may be specific cases where using Metaglip would provide enhanced therapeutic benefits over monotherapy options.
Related trials for metaglip and metformin
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Metaglip typically prescribed?
Oral dosages of Metformin range from 500-2550 mg/day, but studies have shown that a starting dose of 500 mg/day is usually enough for managing Type 2 diabetes in most adults. If required, the dosage can be increased gradually every one to two weeks. For children aged from 10 years and older, they may start on a lower dose of around 500 mg/day. The maximum dosage should not exceed 2550 mg/day in any case. Similarly, oral dosages of Metaglip typically begin with one tablet (containing metformin hydrochloride 500mg and glipizide 2.5mg) twice daily given with meals; if necessary this could be adjusted according to the individual's response after several weeks.
At what dose is Metformin typically prescribed?
Metformin therapy typically begins at a dose of 500 mg taken twice daily or 850 mg once daily. If necessary, the dosage can be increased gradually up to a maximum of 2000-2550 mg per day divided into two or three doses spaced about 12 hours apart. This titration should occur over several weeks to allow your body to adjust and minimize potential side effects, such as gastrointestinal distress. The recommended time for taking Metformin is after meals. However, if there's no adequate response after several weeks at maximum dosage, alternatives may need to be considered.
What are the most common side effects for Metaglip?
Potential side effects of Metaglip, a combination of glipizide and metformin, could include:
- Hypoglycemia (low blood sugar)
- Diarrhea
- Nausea and vomiting
- Asthenia (general weakness and fatigue)
- Upper respiratory infection
- Dizziness
- Abdominal pain
While the commonly reported side effects of Metformin are:
- Gastrointestinal problems such as diarrhea, nausea/vomiting, flatulence
- Indigestion or heartburn
- Headache -Asthenia (general weakness and fatigue)
It's important to note that while these lists contain some similar side effects, not everyone who takes these medications will experience them. If you have any concerns about potential side effects or if you begin experiencing any unusual symptoms after starting one of these drugs, consult your healthcare provider immediately.
Are there any potential serious side effects for Metaglip?
Similar to Metformin, Metaglip also carries potential side effects, albeit they are rare. These can include:
- Hypoglycemia or low blood sugar: symptoms may range from shaking, sweating, rapid heartbeat to severe symptoms like confusion and unconsciousness.
- Allergic reactions: signs such as hives; difficulty breathing; swelling of your face, lips, tongue or throat should warrant immediate medical attention.
- Lactic acidosis (a build-up of lactic acid in the body): This is a serious condition that requires urgent care. Symptoms may include muscle pain or weakness, numbness or cold feeling in your arms and legs, trouble breathing, dizziness, light-headedness or fainting spells.
- Severe skin problems: Although uncommon with Metaglip use alone but still possible are rashes that might involve blisters and peeling skin.
- Visual changes: these could take the form of blurred vision which signals a change in your blood sugar levels.
Always remember if you experience any unusual symptoms after starting on a new medication it's always best to consult with your healthcare provider promptly for advice.
What are the most common side effects for Metformin?
Metformin, a commonly prescribed medication for type 2 diabetes, has potential side effects such as:
- Nausea, vomiting and loss of appetite
- Abdominal discomfort or bloating
- Diarrhea or constipation
- A metallic taste in the mouth
- Headaches and dizziness
- Mild rash
- Weight loss due to improved diet and exercise habits (not directly from the drug)
- Potential low blood sugar episodes resulting in confusion or agitation.
However, it's also important to note that not everyone taking Metformin will experience these side effects. It is recommended that you speak with your healthcare provider about any concerns you may have regarding this medication.
Are there any potential serious side effects for Metformin?
While Metformin is commonly prescribed and typically well-tolerated, it's still important to be aware of potential side effects. Severe adverse reactions might include:
- Symptoms of lactic acidosis: unusual muscle pain or weakness, trouble breathing, stomach discomfort, dizziness or lightheadedness, slow or irregular heartbeat
- Allergic reaction signs such as itching, rash, swelling (especially of the face/tongue/throat), severe dizziness or difficulty breathing
- Yellowing skin or eyes (jaundice)
- Unusual tiredness with sleep problems
- Stomach pains followed by feeling cold and faint
- Unusual changes in mood
If you experience any of these serious side effects when taking Metformin, seek medical attention immediately.
Contraindications for Metaglip and Metformin?
Both Metaglip and Metformin, like many other diabetes medications, may cause side effects such as lactic acidosis. This is a potentially life-threatening condition that can occur due to the buildup of metformin in your body. If you experience symptoms such as unusual muscle pain, trouble breathing, stomach discomfort or increased drowsiness, please seek immediate medical attention.
Neither Metaglip nor Metformin should be taken if you are taking or have recently taken medications for heart disease (particularly those containing iodine), diuretics (water pills), steroids, blood pressure medication or other diabetes medicines without consulting with your physician first. Your doctor needs to know all the current medications that you're on; some of them may require a wash-out period to prevent dangerous interactions with both Metaglip and Metformin.
How much do Metaglip and Metformin cost?
For the brand name versions of these drugs:
- The price of 60 tablets of Metaglip (2.5/500 mg) averages around $450, which works out to $15–30/day, depending on your dose.
- The price for 60 tablets of Metformin (500 mg) is about $390, working out to approximately $13/day.
Consequently, if you are in a higher dosage range for Metaglip (i.e., up to 10/2000 mg per day), then brand-name Metformin is less expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which drug is right for you.
For the generic versions of these medications, costs are significantly lower:
-
Generic metformin hydrochloride (500mg tablets) is available in packs ranging from 30 to 180 tablets with approximate costs from as low as $0.01 to around $0.50 per day depending upon dosage and pill quantity purchased.
-
Glipizide-metformin hydrochloride - the generic version of Metaglip - can have varying prices based on strength and quantity but typically ranges between approximately$0.20 and up to over a dollar or more per day depending upon similar factors: strength/dosage level and amount purchased at once.
Popularity of Metaglip and Metformin
Metformin, both in its generic form and under brand names such as Glucophage, was estimated to have been prescribed to about 78.6 million people in the US in 2020. Metformin accounted for just over 53% of all prescriptions for type 2 diabetes medications in the US. With a long history of use since its introduction into clinical practice more than half a century ago, metformin has generally maintained consistent usage trends due to its efficacy and safety profile.
Metaglip is an antidiabetic medication that combines glipizide and metformin. In comparison with Metformin alone, it was prescribed significantly less frequently; around two hundred thousand prescriptions were filled for Metaglip or similar combination drugs during the same year. Its usage accounts for approximately less than 1% of overall antidiabetic medication prescriptions but can be a useful option when monotherapy does not provide adequate blood sugar control.
Conclusion
Both Metaglip (a combination of glipizide and metformin) and Metformin are widely used in the management of type 2 diabetes, with a solid track record backed by numerous clinical studies showing their effectiveness over placebo treatments. Occasionally, these drugs may be combined for more effective blood glucose control; however, this requires careful consideration by a healthcare provider as they can also interact with one another. Their mechanisms of action differ: while Metformin works primarily by decreasing glucose production in the liver and improving insulin sensitivity, Metaglip not only contains metformin but also includes glipizide that stimulates the pancreas to produce more insulin.
Both medications come in generic forms which offer significant cost savings especially for patients who must pay out-of-pocket. Both Metaglip and metformin might require an adjustment period where effects may not be immediately noticeable.
The side effect profiles between these two drugs show similarities yet there are differences worth noting. While both are generally well-tolerated, metformin is known to cause gastrointestinal issues such as diarrhea or nausea more frequently than Metaglip. Patients using either medication should monitor their blood sugar levels regularly especially when starting treatment, and seek immediate medical help if they experience symptoms like severe nausea, hypoglycemia or lactic acidosis.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021, January). Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism. SAGE Publications.http://doi.org/10.1177/2042018820980225
- Krentz, A. J., & Bailey, C. J. (2005). Oral Antidiabetic Agents. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-200565030-00005
- Ashraf, S., Upreti, P., Karki, S., Khan, M., & Nasr, R. (2022, April 17). Metformin-Associated Lactic Acidosis: A Case Report and Review. Cureus. Springer Science and Business Media LLC.http://doi.org/10.7759/cureus.24220
- Raskin, P. (2008, October 29). Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes, Obesity and Metabolism. Wiley.http://doi.org/10.1111/j.1463-1326.2008.00907.x
- Le, S., & Lee, G. C. (2019, May 23). Emerging Trends in Metformin Prescribing in the United States from 2000 to 2015. Clinical Drug Investigation. Springer Science and Business Media LLC.http://doi.org/10.1007/s40261-019-00799-0
- Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., … Bolen, S. (2011, May 3). Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine. American College of Physicians.http://doi.org/10.7326/0003-4819-154-9-201105030-00336
- Gignilliat, J. (1996, October). Re: TDE article, Pharmacy Update, "Metformin: A Biquanide". The Diabetes Educator. SAGE Publications.http://doi.org/10.1177/014572179602200502
- Seck, T. L., Engel, S. S., Williams-Herman, D. E., Sisk, C. M., Golm, G. T., Wang, H., … Goldstein, B. J. (2011, July). Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice. Elsevier BV.http://doi.org/10.1016/j.diabres.2011.03.006
- Iglay, K., Sawhney, B., Fu, A. Z., Fernandes, G., Crutchlow, M. F., Rajpathak, S., & Khunti, K. (2019, December 17). Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes. Endocrinology, Diabetes & Metabolism. Wiley.http://doi.org/10.1002/edm2.107
- Nabrdalik, K., Skonieczna-Żydecka, K., Irlik, K., Hendel, M., Kwiendacz, H., Łoniewski, I., … Lip, G. Y. H. (2022, September 14). Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. Frontiers in Endocrinology. Frontiers Media SA.http://doi.org/10.3389/fendo.2022.975912
- Strack, T. (2008). Metformin: A review. Drugs of Today. Portico.http://doi.org/10.1358/dot.2008.44.4.1138124
- Zheng, J., Woo, S.-L., Hu, X., Botchlett, R., Chen, L., Huo, Y., & Wu, C. (2015, February 12). Metformin and metabolic diseases: a focus on hepatic aspects. Frontiers of Medicine. Springer Science and Business Media LLC.http://doi.org/10.1007/s11684-015-0384-0